Metastatic prostate cancer Clinical Trials
Recruiting metastatic prostate cancer studies with sites across the US, sourced from ClinicalTrials.gov and refreshed daily. Free to join — find one near you below.
Clinical trials study new ways to prevent, detect, or treat metastatic prostate cancer. Joining one can give you access to investigational treatments and close monitoring by a specialist research team — at no cost — while helping advance care for others. Below are recruiting metastatic prostate cancer studies with sites across the US; use the location tools to find ones near you.
What to expect
- Screening first. The study team reviews your eligibility before anything else — there's no obligation to continue.
- Informed consent. You'll get a full explanation of the study, its potential risks and benefits, and can withdraw at any time.
- No cost to you. Study visits, tests, and the investigational treatment are covered; many studies reimburse travel.
Recruiting metastatic prostate cancer trials
Phase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate Cancer
PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan
Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)
Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer
Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy
Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial
Prostate Radiotherapy and Metastasis-Directed Therapy in Synchronous Oligometastatic Prostate Cancer
PSMA PET-Guided Progression-Directed Radiotherapy for Oligoprogressive Prostate Cancer
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer
First-in-human Diagnostic Imaging Profile of the Theranostic Pair [68Ga]Ga-DOTA-STR-17126 and Low Dose [177Lu] Lu-DOTA-STR-17126 in Patients With Advanced or Metastatic Cancer
First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
PROMET-BR - Molecular Profiling of Metastatic Prostate Cancer: a Brazilian Cohort
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium
177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC
Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy
Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN)
Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers
A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer
A Phase I Trial of A-CAR032 in Participants With mCRPC
Pharmaceutical Management in Targeted Radioligand Therapy
Physician- and Patient-based Barriers to NGS Testing
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
Clinical Trial to Evaluate the Tolerance of TQB3201 Tablets
The COSMYC Trial (COmbined Suppression of MYC)
Comparison of Different Methods of CAPTure of Circulating Tumour Cells (CTC) in Patients With Metastatic Breast or Prostate Cancer
A Study of Tarlatamab for People With Prostate Cancer
Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer
Impact of Multimodal Telerehabilitation in Rural Patients With Metastatic Prostate Cancer
Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617
Post Marketing Study on Pluvicto in Korea
Study of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate Cancer
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
Prostate Cryoablation Combined With Metronomic Cyclophosphamide for Metastatic Prostate Cancer
Study of HLD-0915 in Patients With Metastatic Prostate Cancer
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes
18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer
Radiotherapy Combined With Fluzopanib and Abiraterone Acetate Tablets (II) Treatment for mCRPC
Metastatic prostate cancer clinical trials — common questions
Are metastatic prostate cancer clinical trials free to join?
Yes. Participating in a metastatic prostate cancer clinical trial is free — study-related visits, tests, and the investigational treatment are provided at no cost to you. Many studies also reimburse travel and time. You never pay to take part.
Who can join a metastatic prostate cancer clinical trial?
Each metastatic prostate cancer study sets its own eligibility criteria — typically based on age, medical history, current treatments, and overall health. Every trial listed here shows its criteria, and the study team confirms your eligibility before enrollment. You can review and apply to any that look like a fit.
How do I find a metastatic prostate cancer trial near me?
Use the location controls above. We'll show recruiting metastatic prostate cancer trials with sites near you, sorted by distance. You can widen the radius or share your exact location for the closest matches.
How many metastatic prostate cancer trials are recruiting right now?
We're currently tracking roughly 69 recruiting metastatic prostate cancer trials with US sites, sourced from ClinicalTrials.gov and refreshed daily.
Looking for a specific location? Browse trials by city and state.